-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
BRD3308
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/1550053-02-5.gif)
| Category | Human immunodeficiency Virus (HIV) |
| CAS | 1550053-02-5 |
| Description | BRD3308 is a highly selective HDAC3 inhibitor with IC50 of 54 nM. BRD3308 inhibits pancreatic β-cell apoptosis induced by inflammatory cytokines or glycolipid toxic stress, and increases the release of functional insulin. BRD3308 activates HIV-1 transcription and destroys the HIV-1 incubation period. |
Product Information
| Synonyms | 4-Acetylamino-N-(2-Amino-4-Fluorophenyl)-Benzamide; CHEMBL4293858; SCHEMBL15551809; BDBM178100 |
| IUPAC Name | 4-acetamido-N-(2-amino-4-fluorophenyl)benzamide |
| Molecular Weight | 287.29 |
| Molecular Formula | C15H14FN3O2 |
| Canonical SMILES | CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=C(C=C2)F)N |
| InChI | InChI=1S/C15H14FN3O2/c1-9(20)18-12-5-2-10(3-6-12)15(21)19-14-7-4-11(16)8-13(14)17/h2-8H,17H2,1H3,(H,18,20)(H,19,21) |
| InChIKey | RRJDFENBXIEAPD-UHFFFAOYSA-N |
| Boiling Point | 449.9±45.0 °C(Predicted) |
| Flash Point | 225.9±28.7 °C |
| Purity | 98% |
| Density | 1.382±0.06 g/cm3(Predicted) |
| Solubility | Soluble in DMF (30 mg/ml), DMSO (30 mg/ml), Ethanol (30 mg/ml) |
| Appearance | Off-white to light yellow (Solid) |
| Storage | Store at -20°C |
| Complexity | 383 |
| Exact Mass | 287.10700486 |
| Index Of Refraction | 1.689 |
| In Vitro | BRD3308 (5-30 µM; 6-24 hours) treatment increases HIV-1 expression in the 2D10 cell line. BRD3308 (15 µM; overnight) is able to induce outgrowth of HIV-1 from latently infected cells ex vivo in resting CD4+ T cells. BRD3308 inhibits HDAC1, HDAC2 and HDAC3 with Ki values of 5.1 μM, 6.3 μM and 29 nM, respectively. |
| In Vivo | BRD3308 reduced hyperglycaemia and increased insulin secretion in a rat model of type 2 diabetes. |
| Target | HDAC; HIV; Apoptosis |
| Vapor Pressure | 0.0±1.1 mmHg at 25°C |
| XLogP3-AA | 1.4 |
